title: A tonsillar PolyICLC/AT-2 SIV therapeutic vaccine maintains low viremia following antiretroviral therapy cessation.
abstract: BACKGROUND
  HIV-infected individuals rely on antiretroviral therapy (ART) to control viral replication. Despite abundant demonstrable benefits, the multiple limitations of ART point to the potential advantages of therapeutic vaccination approaches that could provide sustained host control of viral replication after discontinuation of ART. We provide evidence from a non-human primate model that a therapeutic vaccine applied to the tonsils can maintain low viral loads after cessation of ART.
  
  
  RESULTS
  Animals received 40 weeks of ART initiated 9 weeks after rectal SIVmac239 infection. During ART, animals were vaccinated (or not) with AT-2 inactivated SIVmac239 using CpG-C ISS-ODN (C274) or polyICLC as adjuvants. PolyICLC/AT-2 SIV vaccinated animals maintained viral loads <3×10(3) copies/ml for up to 16 weeks post-ART, whereas the C274/AT-2 SIV vaccinated and non-vaccinated animals' viremia ranged between 1×10(4)-4×10(5) copies/ml (p<0.03). Neutralizing Ab activity in plasma was increased by polyICLC/AT-2 tonsillar vaccination under ART, compared to controls (p<0.03). Subsequent vaccination of all animals with polyICLC/AT-2 SIV in the absence of ART did not alter viral loads. Other immune parameters measured in blood and tissues were comparable between groups.
  
  
  CONCLUSIONS
  These results provide support for the potential benefit of mucosally delivered vaccines in therapeutic immunization strategies for control of AIDS virus infection.
authors.affiliation: HIV/AIDS Program, Population Council, Center for Biomedical Research, New York, New York, USA.
authors.forename: Panagiotis
authors.initials: P
authors.lastname: Vagenas
authors.forename: Meropi
authors.initials: M
authors.lastname: Aravantinou
authors.forename: Vennansha G
authors.initials: VG
authors.lastname: Williams
authors.forename: Edith
authors.initials: E
authors.lastname: Jasny
authors.forename: Michael
authors.initials: M
authors.lastname: Piatak
authors.forename: Jeffrey D
authors.initials: JD
authors.lastname: Lifson
authors.forename: Andres M
authors.initials: AM
authors.lastname: Salazar
authors.forename: James L
authors.initials: JL
authors.lastname: Blanchard
authors.forename: Agegnehu
authors.initials: A
authors.lastname: Gettie
authors.forename: Melissa
authors.initials: M
authors.lastname: Robbiani
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D004195:Disease Models, Animal; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology* / Q000821:virology; D015497:HIV-1 / Q000276:immunology; D006801:Humans; D008253:Macaca mulatta; D008297:Male; D014066:Palatine Tonsil / Q000276:immunology* / Q000821:virology; D018449:SAIDS Vaccines / Q000008:administration & dosage / Q000276:immunology; D016097:Simian Acquired Immunodeficiency Syndrome / Q000188:drug therapy / Q000276:immunology / Q000821:virology; D015302:Simian Immunodeficiency Virus / Q000276:immunology*; D014611:Vaccination; D019562:Viral Load; D014766:Viremia / Q000276:immunology* / Q000821:virology; D028761:Withholding Treatment
chemical_list: D000276:Adjuvants, Immunologic; D044966:Anti-Retroviral Agents; D018449:SAIDS Vaccines